Valuation
- Market cap
- 884,181,000
- Revenue TTM
- $107,460,000
- Net income TTM
- $105,900,000
- PE ratio
- 0.00
- Forward PE
- 10.92
- Profit margin
- 98.55%
- Debt to equity
- 0.00
Trading
- Volume
- 10,043,399
- Avg volume
- 807,250
- Day's range
- $17.02 – $17.07
- Shares out
- 51,919,000
- Stochastic %K
- 38%
- Beta
- 0.25
- Analysts
- Hold
- Price target
- $17.33
Company profile
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic...
Show more
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 650 808 6000
- Website
- https://www.theravance.com
- Address
- 901 Gateway Boulevard, South San Francisco, United States
Latest news
No headlines yet.
